MTA1 and prostate carcinoma: In addition to PSA recurrence, which is the first indication of prostate cancer progression, we next determined if the protein levels of YB-1 and MTA1 correlate with clinically relevant end points beyond changes in the PSA level including future need for androgen deprivation therapy or radiation therapy.